Table 1 A comparative presentation of pathways identified for AMS-R and AMS-S phenotypes using IPA
From: Human adaptation to high altitude: a review of convergence between genomic and proteomic signatures
Sr. no | Ingenuity canonical pathways | −log p value | Molecules |
|---|---|---|---|
AMS-R | |||
1 | Complement System | 14.9 | C4A/C4B, C5, C6, C7, C8A, C8B, C8G, CFH |
2 | Acute-Phase Response Signaling | 7.5 | APCS, C4A/C4B, C5, CRP, ITIH3, KLKB1, RBP4 |
3 | LXR/RXR Activation | 7.11 | APOA5, APOE, C4A/C4B, GC, HPR, RBP4 |
4 | FXR/RXR Activation | 5.56 | APOE, C4A/C4B, GC, HPR, RBP4 |
5 | Systemic Lupus Erythematosus Signaling | 4.09 | C5, C6, C7, C8A, C8B, C8G |
AMS-S | |||
1 | Complement System | 9.34 | C1QBP, C4A/C4B, C6, C8A, C8B, C8G, CFH |
2 | LXR/RXR Activation | 9.34 | APOA5, APOE, C4A/C4B, GC, HPR, KNG1, RBP4 |
3 | EIF2 Signaling | 4.96 | EIF3B, RPL10A, RPL18A, RPS10, RPS14, RPS25, RPS26, RPS27 |
4 | Regulation of elF4 and p70S6K Signaling | 4.56 | EIF3B, ITGB1, RPS10, RPS14, RPS25, RPS26, RPS27 |
5 | FXR/RXR Activation | 4.42 | APOE, C4A/C4B, GC, HPR, KNG1, RBP4 |